# NAD+ precursors: NMN, NR

> NAD+ and the longevity claim | Peptide Empire — Peptide Empire separates NAD+ from peptides and follows NMN and NR trials through blood measurements, muscle insulin sensitivity, walking and aging claims.

**The longevity annex**

A coenzyme has acquired a large longevity reputation. The more interesting human results concern smaller, measurable changes.

## How NAD+ entered this company

NAD+ sits awkwardly in a publication about peptides because it is a coenzyme. Its chemistry differs from a chain of amino acids. Cells use it to transfer electrons during energy metabolism, and enzymes consume it in processes including DNA repair and regulation of inflammation. The [review of NAD+ metabolism during ageing](https://pubmed.ncbi.nlm.nih.gov/33353981/) explains why that biology has attracted so much interest.

The appeal is easy to understand: replenish something essential and the cell might work better. The more ambitious version would make that replenishment a means of slowing human aging. The distance between those propositions is where the research becomes interesting.

Most controlled human studies here involved NMN or NR, starting materials that the body can use to make NAD+. Taking a precursor by mouth is its own intervention, with findings that concern that substance and route.

## Blood NAD+ concentrations

An [eight-week trial of oral NR in healthy overweight adults](https://pubmed.ncbi.nlm.nih.gov/31278280/) found blood NAD+ increases of 22%, 51% and 142% in groups receiving different amounts. Adverse events did not differ significantly from placebo. This is fairly direct evidence that the intervention changed the measured blood pool over that study period.

I give a result like that its due. It establishes something necessary to the proposed biological story. It leaves the next questions open: which tissues changed, and whether that change improved a person’s health or daily functioning. The [2025 review of human NAD+ precursor trials](https://pubmed.ncbi.nlm.nih.gov/41083806/) describes sparse tissue-specific data and limited evidence of broad clinical efficacy.

## Muscle insulin response; walking distance

A [ten-week NMN study in prediabetic women after menopause](https://pubmed.ncbi.nlm.nih.gov/33888596/) found improved muscle insulin sensitivity: insulin helped glucose enter muscle more effectively. Body composition and HbA1c, a longer-term blood-sugar measure, did not change. The result deserves that full description. It concerns a particular tissue response in a small, defined group.

A separate [sixty-day NMN trial in middle-aged adults](https://pubmed.ncbi.nlm.nih.gov/36482258/) reported greater walking distances and improved quality-of-life scores compared with placebo, alongside higher blood NAD+. No safety issues were reported at the studied amounts during that trial.

The walking and muscle findings make NMN tangible to me. Those outcomes give an ambitious biological hypothesis something concrete to answer for. Neither trial tested whether people lived longer.

![Two staff members measure a bright corridor and arrange plain cones](images/walking-test-preparation.webp)

*An imagined scene of staff preparing a walking-test corridor. The NMN trial reported walking distance; this scene does not depict its participants or actual setting.*

## Aging claims and safety limits

The [human clinical review published in 2025](https://pubmed.ncbi.nlm.nih.gov/41083806/) found that an age-related NAD+ decline had been consistently observed in only a limited number of human studies. Tissue measurements remain sparse. Rodent results helped motivate the field, but longevity findings in rodents leave human lifespan a separate question.

The short [NMN](https://pubmed.ncbi.nlm.nih.gov/36482258/) and [NR](https://pubmed.ncbi.nlm.nih.gov/31278280/) studies give some information about tolerability during their follow-up. They cannot establish lifetime safety, pregnancy safety or the effects of a compounded injectable preparation. NAD+ products have no drug approval; pills containing precursors and NAD+ given through a vein also have different evidence behind them.

Because both healthy and diseased cells use NAD+, there are theoretical questions about supporting the metabolism of an existing cancer. The studies discussed here do not demonstrate a cancer risk caused by precursor supplementation. NAD+’s cancer questions deserve an experiment with explicit cancer outcomes.

Broad claims about energy, clearer thinking or rejuvenation still exceed the human outcomes established here. I would welcome longer functional studies far more than a larger collection of blood-level increases.

---

Peptide Empire audits how peptide claims cross from mechanism into medicine; it is an independent literature digest, not clinical direction.